Brief: Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy
03/04/2025 12:35
April 3 (Reuters) - Intellia Therapeutics Inc NTLA.O: INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY INTELLIA THERAPEUTICS INC: PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028 Source text: ID:nGNX1L2QP0 Further company coverage: NTLA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)